GlassScriptPhysician profile
Heba Mahmoud
NPI 1659763365
$1,714.49
in general payments reported to CMS, 2019-2025
21 companies · $60.09 in 2025
The $60.09 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.26 · 2020: $87.20 · 2021: $280 · 2022: $448 · 2023: $535 · 2024: $243 · 2025: $60.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $521.43 | 2021-2025 | Briviact, Fintepla |
| Gilead Sciences, INC. | $256.13 | 2021-2023 | |
| Pfizer INC. | $129.93 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $128.10 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $106.90 | 2019-2024 | Camzyos, Eliquis |
| Melinta Therapeutics, LLC | $99.07 | 2019-2023 | Kimyrsa, Vabomere |
| Intuitive Surgical, INC. | $91.76 | 2023 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.00 | 2021-2023 | Jardiance |
| Paratek Pharmaceuticals, INC. | $56.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $56.58 | 2020-2023 | Recarbrio, Zerbaxa, Dificid |
| Smith+Nephew, INC. | $50.94 | 2024 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $20.75 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $17.13 | 2023 | Arcalyst |
| Phadia US INC. | $16.14 | 2021 | |
| Boston Scientific Corporation | $15.39 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $15.18 | 2023 | Xerava |
| Ferring Pharmaceuticals INC. | $14.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.78 | 2021 | |
| Abiomed | $14.54 | 2023 | Impella |
| Alexion Pharmaceuticals, INC. | $14.16 | 2022 | |
| Abbvie INC. | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heba Mahmoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.